HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
18 hedge funds and large institutions have $6.59M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 7 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
14% less funds holding
Funds holding: 21 → 18 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
68% less capital invested
Capital invested by funds: $20.6M → $6.59M (-$14M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$159K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$159K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$156K |
| 4 |
Bank of New York Mellon
New York
|
+$122K |
| 5 |
BlackRock
New York
|
+$35.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$2.08M |
| 2 |
State Street
Boston,
Massachusetts
|
-$345K |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$209K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$150K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$78.8K |
HTGM Hedge Fund Activity: Q2 2017 in Review
18 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q2 2017, worth a combined $6.59M — down 68% from $20.6M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of HTGM and 4 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Granahan Investment Management, adding an estimated $159K. The largest seller was Putnam Investments, cutting an estimated $2.08M.
- 18 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q2 2017, down from 21 in Q1 2017.
- Funds reported $6.59M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q2 2017, down 68% quarter-over-quarter.
- 4 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q2 2017 and 7 closed out, a net change of -3 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q2 2017 was Granahan Investment Management, an estimated $159K added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q2 2017 was Putnam Investments, an estimated $2.08M sold.
Based on aggregated 13F filings for Q2 2017.